8-K: HCW Biologics Faces Nasdaq Delisting After Failing to Meet Minimum Bid Price and Market Value Requirements

HCW Biologics Inc. is at risk of being delisted from the Nasdaq Stock Market after failing to regain compliance with the minimum bid price and market value requirements.

Summary

• HCW Biologics Inc. received notification from Nasdaq on February 5, 2025, that its securities are subject to delisting.
• This is due to the company's failure to meet the minimum bid price of $1 per share and the minimum market value of publicly held securities (MVPHS) of $15,000,000 by the compliance deadlines of February 3, 2025, and February 4, 2025, respectively.
• The company had previously received notices regarding these deficiencies on August 12, 2024.
• HCW Biologics also received a notice on December 23, 2024, regarding non-compliance with the minimum market value of listed securities (MVLS) of $50,000,000.
• The company has requested a hearing before the Nasdaq Hearing Panel to present its plan for regaining compliance.
• There is no assurance that the Panel will grant the company's request for continued listing or that the company will be able to evidence compliance within the granted timeframe.
• The Panel has the authority to grant an extension of up to 180 days from the date of the Nasdaq Staff's determination letter received on December 17, 2024.
• The company is considering all available options to regain compliance with Nasdaq Listing Rules.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and uncertainty regarding the company's ability to regain compliance with Nasdaq listing rules. While the company is taking steps to address the issue, the outcome is uncertain.

Positives

• HCW Biologics has requested a hearing before the Nasdaq Hearing Panel to present its plan for regaining compliance.
• The Nasdaq Hearing Panel has the authority to grant the Company an extension of up to 180 days from the date of the Nasdaq Staff's determination letter the Company received on December 17, 2024.

Negatives

• HCW Biologics received a delisting notice from Nasdaq on February 5, 2025.
• The company failed to meet the minimum bid price and MVPHS requirements for continued listing.
• There is no assurance that the Nasdaq Hearing Panel will grant the company's request for continued listing.

Risks

• The company's securities are subject to delisting from Nasdaq.
• There is no guarantee that the company will be able to regain compliance with Nasdaq Listing Rules.
• Failure to regain compliance could negatively impact the company's stock price and ability to raise capital.

Future Outlook

The company will present its plan to evidence compliance with all applicable listing criteria at the hearing before the Nasdaq Hearing Panel and is considering all options available to it to regain compliance with all Listing Rules.

Management Comments

• The Company is considering all options available to it to regain compliance with all Listing Rules.

Industry Context

Delisting notices are not uncommon for companies facing financial difficulties or market downturns, and the outcome often depends on the company's ability to present a credible plan for recovery and compliance.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment if the company is delisted.
• Employees may face uncertainty regarding their job security.
• The company's ability to raise capital and fund its operations may be negatively impacted.

Next Steps

• The Company will present its plan to evidence compliance with all applicable listing criteria, including the MVLS Rule, the Bid Price Rule and the MVPHS Rules at the hearing before the Nasdaq Hearing Panel.
• The Company is considering all options available to it to regain compliance with all Listing Rules.

Key Dates

Keywords

delisting, Nasdaq, compliance, HCW Biologics, minimum bid price, MVPHS, MVLS